NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies

Autor:	Sabrina Cribioli, Rachele Alzani, Antonella Isacchi, M. Ciomei, Daniele Casero, Alessia Montagnoli, Daniele Donati, Arturo Galvani, Nadia Amboldi, A. Lombardi Borgia, Nilla Avanzi, L. Mancini, Wilma Pastori, Elena Ardini, Gemma Texido, M. Montemartini
Rok vydání:	2016
Předmět:	Cancer Research Oncology Tolerability business.industry Medicine Pharmacology business
Zdroj:	European Journal of Cancer. 69:S127-S128
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(16)32980-x
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::45d5e213370d6e7c6f96761bab6290d6 https://doi.org/10.1016/s0959-8049(16)32980-x Zobrazit plný text záznamu Full Text from ScienceDirect